ドーパミン受容体アゴニスト (フェノルドーパム) の即時血液動力学的効果は,本質的な高血圧の患者において
Circulation
|June 1, 1984
まとめ
新型ドーパミン受容体アゴニストであるフェノルドパムは,全周回路抵抗を減らし,心電量を増やすことで血圧を効果的に低下させます. また,スプランク血動力学やホルモンレベルに影響を与えることなく,腎臓の血流を増強します.
科学分野:
- 薬理学 薬理学とは
- 心血管生理学 心血管の生理学
- ネフロロジーはネフロロジーを用います.
背景:
- 高血圧は,世界的な健康上の大きな課題であり続けています.
- ドーパミン受容体アゴニストは,血圧管理のための潜在的な治療方法を表しています.
- 新型抗高血圧薬の全身的血液動力学的効果を理解することは,臨床応用において極めて重要です.
研究 の 目的:
- 選択的なドーパミン受容体アゴニストであるフェノルドパムの単一投与による血液動力学および内分泌学的効果を評価する.
- フェノルドパムの全身,体,腎臓の循環への影響を評価する.
- フェノルドパム投与後の血管内容量およびホルモンプロフィールの変化を測定する.
主な方法:
- 参加者にはフェノルドパムの単回投与を施した.
- 薬剤投与前と後に,全身的,スプランク的,腎臓の血液動力学的パラメータを測定した.
- 血管内容量,血レニン活性,ノルエピネフリン,アルドステロン,プロラクチンレベルをモニタリングした.
主要な成果:
- フェノルドパムは,主に全周回路抵抗の減少を通じて,平均動脈圧を13%低下させた.
- 心臓指数,心拍数,脳卒中量,左心室排泄率が増加し,心臓の性能が向上したことを示しています.
- 腎臓の血流が有意に増加した (腎血管抵抗が40%以上減少した),一方,スプランク血動力学は変化しなかった.
- 血管内容量,血レニン活性,ノルエピネフリン,アルドステロン,またはプロラクチンレベルの有意な変化は観察されなかった.
結論:
- フェノルドーパムは,血管拡張と心臓機能の改善によって媒介される強力な抗高血圧効果を示しています.
- この薬は,腎臓の血流を選択的に強化し,腎臓 perfusion への潜在的な利点を示唆しています.
- フェノルドーパムは,研究された用量では,スプランク循環や主要な内分泌系に有意な影響を与えるようには見えません.
関連する概念動画
Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...


